China RUO Immunoassay Market Size, Share, Opportunities, And Trends By Product Type (Immunoassay Kits, Immunoassay Reagents, Microplate Reader, Microplates, Analyzers (Automated Analyzers, Non-Automated Analyzers), Microplate Washers, Others), By Sample Type (Plasma, Blood Serum, Urine, Saliva, Cell or Tissue Culture Medium, Others), By Application (Oncology, Blood Screening and Toxicology, Infectious Disease, Cardiology, Allergy Diagnostic, Rare and Emerging Condition Diagnostic, Others), By End-User (Research and Academic Laboratories, Pharmaceutical and Biotechnology Companies), And By State - Forecasts From 2025 To 2030

China RUO Immunoassay Market Size:

The China RUO immunoassay market is expected to grow at a CAGR of 14.85% from 2025 to 2030.

Due to the second largest population and being one of the world’s biggest economies, China's RUO immunoassay market is driven by several factors including the high burden of chronic disease ailments, such as diabetes. China's diabetic population (20-79 y) is expected to increase from 140,869.6 in 2021 to 164,069.5 (number in 1,000s), leading to the demand for diagnosis, monitoring, and development treatments for different ailments. According to data from the National Health Commission's website, as of 2021, China had a total of 36,570 hospitals, providing more than 7.4 million beds and serving 3.88 billion patient visits. Public facilities accounted for 70.2% of hospital beds and received 84.2% of patient visits. The favorable support by the government to the healthcare sector is providing the necessary impetus to the RUO immunoassays market growth. 

The innovative products by Chinese companies not only for domestic use are attracting demand for these products from other countries. MAGICL 6000iChemiluminescence Immunoassay Analyzer by Getein Biotech, Inc., automates the identification and measurement of biomarkers associated with thyroid disease, tumors, fertility issues, infectious diseases, bone metabolism disorders, cardiac conditions, diabetes mellitus, inflammation, anemia, and immune globulin levels. It achieves this by analyzing samples of human serum, plasma, whole blood, and urine.   

Automatic Chemiluminescence Immunoassay System, by Biobase Biodusty (Shandong), Co., Ltd., utilizes magnetic particle separation technology, employing magnetic particles as carriers for antibodies. This technology allows for the uniform distribution of magnetic particles within the liquid-phase reaction system, resulting in faster reaction speeds and higher efficiency. The enzymatic chemiluminescence method used ensures a more stable light signal.

Companies like BIOBASE, with over 3,000 personnel across 20+ workshops covering a total area of 932,900 square meters, have established overseas operations. Their business encompasses biomedical products, intelligent manufacturing, scientific equipment, and In Vitro Diagnosis (IVD) instruments and reagents, contributing significantly to market growth in China.

China RUO Immunoassay Market Segmentation

By Product Type

• Immunoassay Kits
  • Enzyme-Linked Immunosorbent Assay (ELISA) Kits
    • Conventional
    • Manual
  • Radioimmunoassay (RIA Kits)
    • Conventional
    • Manual
  • Chemiluminescent Immunoassay (CLIA) Kits
• Immunoassay Reagents
• Microplate Reader
• Microplates
• Analyzers
  • Automated Analyzers
  • Non-Automated Analyzers
• Microplate Washers
• Others

By Sample Type

• Plasma
• Blood Serum
• Urine
• Saliva
• Cell or Tissue Culture Medium
• Others

By Application

• Oncology
• Blood Screening and Toxicology
• Infectious Disease
• Cardiology
• Allergy Diagnostic
• Rare and Emerging Condition Diagnostic
• Others

By End-User

• Research and Academic Laboratories
• Pharmaceutical and Biotechnology Companies

By Province

• Shandong
• Henan
• Jiangsu
• Guangdong
• Others

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

4.1. Product Pipeline

5. CHINA RUO IMMUNOASSAY MARKET BY PRODUCT TYPE

5.1. Introduction

5.2. Immunoassay Kits

5.2.1. Enzyme-Linked Immunosorbent Assay (ELISA) Kits

5.2.1.1. Conventional 

5.2.1.2. Manual

5.2.2. Radioimmunoassay (RIA Kits)

5.2.2.1. Conventional 

5.2.2.2. Manual

5.2.3. Chemiluminescent Immunoassay (CLIA) Kits

5.3. Immunoassay Reagents

5.4. Microplate Reader

5.5. Microplates

5.6. Analyzers

5.6.1. Automated Analyzers

5.6.2. Non-Automated Analyzers

5.7. Microplate Washers

5.8. Others

6. CHINA RUO IMMUNOASSAY MARKET BY SAMPLE TYPE

6.1. Introduction

6.2. Plasma 

6.3. Blood Serum

6.4. Urine

6.5. Saliva

6.6. Cell or Tissue Culture Medium

6.7. Others

7. CHINA RUO IMMUNOASSAY MARKET BY APPLICATION

7.1. Introduction

7.2. Oncology

7.3. Blood Screening and Toxicology

7.4. Infectious Disease

7.5. Cardiology

7.6. Allergy Diagnostic

7.7. Rare and Emerging Condition Diagnostic

7.8. Others

8. CHINA RUO IMMUNOASSAY MARKET BY END-USER

8.1. Introduction

8.2. Research and Academic Laboratories

8.3. Pharmaceutical and Biotechnology Companies

9. CHINA RUO IMMUNOASSAY MARKET BY PROVINCE

9.1. Introduction

9.2. Shandong

9.2.1. By Product Type

9.2.2. By Sample Type

9.2.3. By Application

9.2.4. By End-User

9.3. Henan

9.3.1. By Product Type

9.3.2. By Sample Type

9.3.3. By Application

9.3.4. By End-User

9.4. Jiangsu

9.4.1. By Product Type

9.4.2. By Sample Type

9.4.3. By Application

9.4.4. By End-User

9.5. Guangdong

9.5.1. By Product Type

9.5.2. By Sample Type

9.5.3. By Application

9.5.4. By End-User

9.6. Others

9.6.1. By Product Type

9.6.2. By Sample Type

9.6.3. By Application

9.6.4. By End-User

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. F. Hoffmann-La Roche Ltd

11.2. Merck KGaA

11.3. Fujirebio Inc. (H.U. Group Holdings)

11.4. Danaher Corporation

11.5. Quanterix Corporation

11.6. Thermo Fisher Scientific Inc. 

11.7. QuidelOrtho Corporation

11.8. Canon Medical Diagnostic Corporation

11.9. Becton Dickinson

11.10. Getein BioTech Inc

11.11. Biobase Biodusty(Shandong), Co., Ltd. 

12. APPENDIX

12.1. Currency 

12.2. Assumptions

12.3. Base and Forecast Years Timeline

12.4. Key benefits for the stakeholders

12.5. Research Methodology 

12.6. Abbreviations 

Hoffmann-La Roche Ltd

Merck KGaA

Fujirebio Inc. (H.U. Group Holdings)

Danaher Corporation

Quanterix Corporation

Thermo Fisher Scientific Inc. 

QuidelOrtho Corporation

Canon Medical Diagnostic Corporation

Becton Dickinson

Getein BioTech Inc

Biobase Biodusty(Shandong), Co., Ltd.